Cargando…
Long-Term Safety and Usefulness of Mexiletine in a Large Cohort of Patients Affected by Non-dystrophic Myotonias
Objective: The aim of our study was to evaluate the long-term efficacy and safety of mexiletine in 112 patients affected by genetically confirmed non-dystrophic myotonias. The study was performed at the Neurophysiologic Division of Fondazione Policlinico Universitario A. Gemelli Istituto di Ricerca...
Autores principales: | Modoni, Anna, D'Amico, Adele, Primiano, Guido, Capozzoli, Fiorentino, Desaphy, Jean-François, Lo Monaco, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326038/ https://www.ncbi.nlm.nih.gov/pubmed/32655465 http://dx.doi.org/10.3389/fneur.2020.00300 |
Ejemplares similares
-
Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation
por: Desaphy, Jean-François, et al.
Publicado: (2016) -
Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy
por: Desaphy, Jean-François, et al.
Publicado: (2012) -
The Clinical, Myopathological, and Genetic Analysis of 20 Patients With Non-dystrophic Myotonia
por: Wang, Quanquan, et al.
Publicado: (2022) -
Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes()
por: Desaphy, Jean-François, et al.
Publicado: (2013) -
Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel
por: Chapman, Ann-Marie, et al.
Publicado: (2021)